🇺🇸 FDA
Pipeline program

A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults

EP395-006

Phase 1 other active

Quick answer

A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults for Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)] is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)]
Phase
Phase 1
Modality
other
Status
active

Clinical trials